Prévisions du marché des services de pharmacocinétique en Amérique du Nord jusqu\'en 2031 - Analyse régionale - par type de médicament (petite molécule, grande molécule et vaccins), type de service (études précliniques ADME et humaines, analyse et rapports PK/PD, simulations de dosage, analyse des risques et autres), application thérapeutique (oncologie, maladies infectieuses, troubles neurologiques, maladies auto-immunes, troubles gynécologiques, maladies cardiovasculaires, troubles respiratoires et autres) et utilisateur final (sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat et autres)
L\'élargissement de la gamme d\'application des études pharmacocinétiques alimente le marché des services de pharmacocinétique en Amérique du Nord
Les études pharmacocinétiques sont utilisées pour déterminer plusieurs paramètres tels que le niveau de dose équivalente à l\'homme (HED), la dose sans effet observé (NOEL) et les tests pharmacocinétiques/pharmacodynamiques. L\'objectif principal de tout programme préclinique mené est de soutenir l\'analyse d\'une plage de doses sûre et efficace pour les tests dans les études pharmacocinétiques. Plusieurs études de toxicologie ont recueilli des données sur la NOEL, c\'est-à-dire la dose la plus élevée qui ne produit pas d\'effets indésirables. Ce niveau de dose est ensuite converti en niveau HED sur une base comparative de la surface corporelle s\'il n\'y a pas de données pharmacocinétiques cliniques. La compréhension du profil pharmacocinétique d\'un candidat médicament potentiel joue un rôle important dans le programme de découverte de médicaments. Les autorités réglementaires jouent un rôle majeur dans la mise en œuvre des études pharmacocinétiques. Ces études contribuent également à optimiser les services de soins pharmaceutiques fournis aux patients admis dans les hôpitaux. Le modèle PK est souvent appliqué pour déterminer l\'exposition aux médicaments, les concentrations de médicaments pour analyser le dosage optimal et analyser la disposition des médicaments dans le corps humain. Les prestataires de soins de santé mettent en œuvre les principes de la PK pour concevoir, surveiller les concentrations de médicaments, les doses de certains médicaments, maximiser les résultats thérapeutiques escomptés et minimiser les toxicités.
Aperçu du marché des services de pharmacocinétique en Amérique du Nord
Les États-Unis représentent la plus grande part du marché des services de pharmacocinétique en Amérique du Nord. Le pays est devenu une destination de recherche clinique de premier plan ; il représente environ 50 % du total des essais cliniques menés dans le monde. La disponibilité d\'une infrastructure médicale établie, des délais d\'approbation rapides et un cadre réglementaire favorable créent un environnement propice aux sociétés de recherche pharmaceutique pour mener des essais cliniques. De plus, les données générées dans les essais menés aux États-Unis sont acceptées dans le monde entier. Selon un rapport de l\'Organisation mondiale de la santé (OMS), les États-Unis ont enregistré le plus grand nombre d\'essais cliniques (157 618) en 2021.
Chiffre d\'affaires et prévisions du marché des services de pharmacocinétique en Amérique du Nord jusqu\'en 2031 (en millions de dollars américains)
Segmentation du marché des services de pharmacocinétique en Amérique du Nord
Le marché nord-américain des services de pharmacocinétique est classé en type de médicament, type de service, application thérapeutique, utilisateur final et pays.
En fonction du type de médicament, le marché nord-américain des services de pharmacocinétique est segmenté en petites molécules, grosses molécules et vaccins. Le segment des petites molécules détenait la plus grande part de marché en 2023.
En termes de type de service, le marché nord-américain des services de pharmacocinétique est classé en études précliniques ADME et humaines, analyse et rapports PK/PD, simulations de dosage, analyse des risques, etc. Français Le segment des études précliniques ADME et humaines détenait la plus grande part de marché en 2023.
Par application thérapeutique, le marché nord-américain des services de pharmacocinétique est segmenté en oncologie, maladies infectieuses, troubles neurologiques, maladies auto-immunes, troubles gynécologiques, maladies cardiovasculaires, troubles respiratoires et autres. Le segment de l\'oncologie détenait la plus grande part de marché en 2023.
Par utilisateur final, le marché nord-américain des services de pharmacocinétique est segmenté en sociétés pharmaceutiques et biotechnologiques, organismes de recherche sous contrat et autres. Le segment des organismes de recherche sous contrat détenait la plus grande part de marché en 2023.
Par pays, le marché nord-américain des services de pharmacocinétique est segmenté en États-Unis, Canada et Mexique. Les États-Unis ont dominé la part de marché des services de pharmacocinétique en Amérique du Nord en 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; et SGS SA sont quelques-unes des principales sociétés opérant sur le marché des services pharmacocinétiques en Amérique du Nord.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. North America Pharmacokinetics Services Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Chronic and Infectious Diseases
5.1.2 Expanding Range of Application of Pharmacokinetic Studies
5.1.3 Outsourcing of Pharmacokinetics Services to CROs
5.2 Market Restraints
5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.3 Market Opportunities
5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.4 Future Trend
5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.5 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market - North America Analysis
6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
7. North America Pharmacokinetics Services Market Analysis - by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Pharmacokinetics Services Market Analysis - by Service Type
8.1 Overview
8.2 Pre-Clinical ADME and Human Studies
8.2.1 Overview
8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 PK/PD Analysis and Reporting
8.3.1 Overview
8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Dosing Simulations
8.4.1 Overview
8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Risk Analysis
8.5.1 Overview
8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Pharmacokinetics Services Market Analysis - by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11. North America Pharmacokinetics Services Market - Country Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for Pharmacokinetic Services Market
List of Tables
Table 1. North America Pharmacokinetics Services Market Segmentation
Table 2. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 11. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 12. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 13. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Glossary of Terms
List of Figures
Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. North America Pharmacokinetics Services Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 6. North America Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 7. Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 10. North America Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 16. North America Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 25. North America Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Pharmacokinetics Services Market by Key Countries - Revenue (2023) (US$ Million)
Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 31. United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
Figure 33. Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031(US$ Million)
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- Certara Inc.
- Parexel International Corp
- Thermo Fisher Scientific Inc.
- Allucent
- PACIFIC BIOLABS
- SGS SA
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.